S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet

Relay Therapeutics (RLAY) Stock Forecast & Price Target

$10.08
+0.06 (+0.60%)
(As of 03/1/2024 ET)

Relay Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Analysts' Consensus Price Target

$24.17
139.75% Upside
High Forecast$33.00
Average Forecast$24.17
Low Forecast$12.50
TypeCurrent Forecast
3/4/23 to 3/3/24
1 Month Ago
2/2/23 to 2/2/24
3 Months Ago
12/4/22 to 12/4/23
1 Year Ago
3/4/22 to 3/4/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$24.17$24.61$24.83$31.71
Predicted Upside139.75% Upside106.55% Upside111.91% Upside51.70% Upside
Get Relay Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.


RLAY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RLAY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Relay Therapeutics Stock vs. The Competition

TypeRelay TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside139.75% Upside1,800.15% Upside6.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/22/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/22/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$25.00 ➝ $30.00+181.69%
12/11/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$19.00 ➝ $17.00+81.43%
8/9/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$33.00+195.17%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
5/5/2023JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$28.00 ➝ $24.00+113.90%
4/20/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Hold$16.00 ➝ $12.50+1.21%
4/19/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$42.00 ➝ $29.00+134.82%
4/19/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeOutperform ➝ Strong-Buy$29.00+149.57%
4/19/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$23.00 ➝ $15.00+29.09%
3/9/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$45.00 ➝ $28.00+65.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:21 PM ET.












RLAY Price Target - Frequently Asked Questions

What is Relay Therapeutics's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Relay Therapeutics stock is Moderate Buy based on the current 2 hold ratings, 7 buy ratings and 1 strong buy rating for RLAY. The average twelve-month price prediction for Relay Therapeutics is $24.17 with a high price target of $33.00 and a low price target of $12.50. Learn more on RLAY's analyst rating history.

Do Wall Street analysts like Relay Therapeutics more than its competitors?

Analysts like Relay Therapeutics more than other Medical companies. The consensus rating score for Relay Therapeutics is 2.90 while the average consensus rating score for medical companies is 2.68. Learn more on how RLAY compares to other companies.

Does Relay Therapeutics's stock price have much upside?

According to analysts, Relay Therapeutics's stock has a predicted upside of 106.70% based on their 12-month stock forecasts.

What analysts cover Relay Therapeutics?

Relay Therapeutics has been rated by HC Wainwright, Leerink Partnrs, and Stifel Nicolaus in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:RLAY) was last updated on 3/3/2024 by MarketBeat.com Staff